The biotechnology R&D intensity in Germany's business sector has exhibited moderate fluctuations over the past few years. The data shows a slight decline in recent years, with a peak in 2019 at 0.095 units of value added before declining to 0.09 units and stabilizing there onwards.
The year-on-year variation highlights a downward trend, particularly from 2021 to 2023, showing negative growth rates at -2.57%, -0.023%, and -0.046%, respectively. The Compound Annual Growth Rate (CAGR) from 2017 to 2023 indicates an average negative growth rate, implying a slight contraction in biotechnology R&D intensity.
Looking to the future, the forecast for 2024 to 2028 predicts the R&D intensity will remain stable at 0.09 units. However, with a projected CAGR of -0.04%, there is an expected slight annual decrease, indicating that growth might be stunted.
Future trends to watch for include:
- Potential policy changes that might affect R&D funding.
- Emerging technologies and their influence on R&D investments.
- Global economic factors that might impact the biotechnology sector.
